APP and hepatocellular carcinoma: As shown in Figure S2A, PANX1 had a much low somatic mutation rate in different HCC datasets (0.82% in MERiC/Basel, Nat Commun, 2022 [29]; 0.54% in TCGA, Firehose Legacy; and 0.27% in TCGA, PanCancer Atlas) [30], and APP also displayed a low mutation rate in different HCC datasets (1.64% in TCGA, PanCancer Atlas [30]; 1.61% in TCGA, Firehose Legacy; 0.82% in MERiC/Basel Nat Commun.